À¶Ý®ÊÓƵ

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

Trial ID or NCT#

NCT06646627

Status

recruiting iconRECRUITING

Purpose

This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

Official Title

Phase I Clinical Trial of Autologous B7-H3 Chimeric Receptor (CAR) T Cells in Adults With Recurrent, Platinum Resistant Ovarian Tumors

Eligibility Criteria

Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Oliver Dorigo, M.D., Ph.D.
Oliver Dorigo, M.D., Ph.D.
Gynecologic oncologist, Medical oncologist, Gynecologic oncologist
Mary Lake Polan Professor

Contact us to find out if this trial is right for you.

Contact

Bela Shah
650-723-0594

View on